The KRISTINE study [9] further confirmed that, compared with trastuzumab emtansine (T-DM1) + pertuzumab, the trastuzumab, pertuzumab, docetaxel, and carboplatin-based (TCbHP) regimen in neoadjuvant therapy for HER2-positive breast cancer demonstrated superior efficacy (pCR: 55.7% vs. 44.4%) and safety. This evidence concerns the gene ERBB2 and breast carcinoma.